Drug Discovery Opinion

The World Health Organisation estimates that one third of the world’s population is latently infected with Mycobacterium tuberculosis (MTB), and that ten per cent of infected individuals will develop active disease. Current treatments for tuberculosis are effective only during active infection, and the emergence of drug-resistant strains of MTB is compromising the efficacy of existing drugs. Nicotinamide adenine dinucleotide (NAD⁺) synthetase is an attractive target for control of MTB since the enzyme is essential for survival of both active and latent mycobacteria, but drug discovery efforts against this enzyme have so far been hampered by a lack of structural information.

University of Maryland scientists have now characterised the structure and mechanism of the MTB synthetase and hope that their work will facilitate the discovery of new drugs that will be able to combat both latent and active MTB infections. All living cells need the coenzyme, NAD⁺, which regulates many physiological processes including redox reactions. A number of biochemical pathways are able to synthesise NAD⁺ but, since MTB has only two pathways – both involving NAD⁺ synthetase – and humans have pathways that avoid NAD⁺ synthetase, an inhibitor of this enzyme should be effective against MTB but have minimal side effects.

The MTB NAD⁺ synthetase is a multifunctional enzyme which catalyzes the ATP-dependent formation of NAD⁺ at the synthetase domain using ammonia derived from L-glutamine in the glutaminase domain. The study, which is published in full in Nature Structural & Molecular Biology, revealed a homooctameric subunit organization, suggesting a tight dependence of catalysis on the quaternary structure.

Bookmark It

Hide Sites

Related posts:

1. TB confirmed in 9000 year old human remains Tuberculosis is a major global cause of death and disease, with around one third of the world’s population believed to...
2. Targeting the MTB Proteasome The ability of Mycobacterium tuberculosis (MTB) to establish latent infection poses significant problems in the treatment of TB, but a...
3. Now iSee Ever had difficulty following a structural biology paper? Well, the Structural Genomics Consortium (SGC) and PLoSone have got together to...
4. Allosteric PDE4 Inhibitors with Reduced Potential for Side Effects The cyclic nucleotide phosphodiesterases (PDEs) are important regulators of signal transduction and selective inhibitors of the different subtypes have great...
5. Influenza ‘Cap Snatcher’ Identified Seasonal epidemics of the influenza virus continue to kill hundreds of thousands of people annually, and the increasing incidence of...

Related posts brought to you by Yet Another Related Posts Plugin.

 Email This Post

This entry was posted on Thursday, April 2nd, 2009 at 8:30 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.